Lyndra has secured $23m Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink Capital, Suffolk Equity, Partners Healthcare among others.
PureTech Health has launched a new immuno-oncology programme to develop monoclonal antibodies to target newly discovered immunosuppressive mechanisms in pancreatic cancer and other solid tumours.
Accenture and TransCelerate BioPharma's subsidiary BioCelerate have partnered to advance biopharmaceutical innovation through increased insights in research & development.
Eisai and Meiji Seika Pharma have entered into a license agreement for the commercialization of safinamide for Parkinson's disease treatment in Japan and Asia.
Sucampo Pharmaceuticals has acquired rare disease company Vtesse for upfront consideration of $200m.
Verona Pharma has announced new collaborations with two European technology companies to develop its first-in-class product candidate RPL554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Clinical-stage immuno-oncology firm Agenus is reorganizing its business and operations to straighten its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program.
Warp Drive Bio has partnered with GSK to discover potential therapeutics in oncology and other diseases.
University of Dundee in the UK has been awarded almost £1m to boost efforts to identify new new antibiotics to tackle bacterial infections.
PureTech Health has signed a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.